Intact and internally cleaved free prostate-specific antigen in patients with prostate cancer with different pathologic stages and grades

Urology

Volumn 77, Issue 4, 2011, Pages 1009.e1-1009.e8

  Peltola, Mari T ^a   Niemelä, Pauliina ^a   Väisänen, Ville ^a   Viitanen, Tommi ^a   Alanen, Kalle ^a   Nurmi, Martti ^a   Pettersson, Kim ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CANCER PATIENT; CANCER STAGING; FOLLOW UP; GLEASON SCORE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; WORLD HEALTH ORGANIZATION;

EID: 79953836735     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.11.007     Document Type: Article

References (30)

1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
2. Jhaveri FM, Klein EA, Kupelian PA, et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol. 1999;17:3167-3172. (Pubitemid 29470647)
3. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. New York: Wiley-Liss; 1997.
4. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111:58-64.
5. Mostofi FK. Grading of prostatic carcinoma. Cancer Chemother Rep. 1975;59:111-117.
6. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:1095-1101.
7. Shariat SF, Abdel-Aziz KF, Roehrborn CG, et al. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/mL. Eur Urol. 2006;49:293-302. (Pubitemid 43197868)
8. Wenske S, Korets R, Cronin AM, et al. Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy. Int J Cancer. 2009;124:659-663.
9. Shariat SF, Karakiewicz PI, Margulis V, et al. Inventory of prostate cancer predictive tools. Curr Opin Urol. 2008;18:279-296. (Pubitemid 351489379)
10. Peter J, Unverzagt C, Krogh TN, et al. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res. 2001;61:957-962. (Pubitemid 32174411)
11. Mikolajczyk SD, Marker KM, Millar LS, et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001;61:6958-6963. (Pubitemid 32896525)
12. Wang TJ, Slawin KM, Rittenhouse HG, et al. Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies. Eur J Biochem. 2000;267:4040-4045. (Pubitemid 30436096)
13. Nurmikko P, Vaisanen V, Piironen T, et al. Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin Chem. 2000;46:1610-1618.
14. Nurmikko P, Pettersson K, Piironen T, et al. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem. 2001;47:1415-1423. (Pubitemid 32678820)
15. Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate cancer screening in Göteborg, Sweden. BMC Med. 2008;6:19.
16. Vickers AJ, Cronin AM, Roobol MJ, et al. Reducing unnecessary biopsy during prostate cancer screening using a four kallikrein panel: an independent replication. J Clin Oncol. 2010;28:2493-2498.
17. Piironen T, Pettersson K, Suonpaa M, et al. In vitro stability of free prostate-specific antigen (PSA) complexed to alfa1-antichymotrypsin in blood samples. Urology. 1996;48:81-87.
18. Lilja H, Christensson A, Dahlen U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991;37:1618-1625. (Pubitemid 21905228)
19. Rajakoski K, Piironen T, Pettersson K, et al. Epitope mapping of human prostate specific antigen and glandular kallikreins expressed in insect cells. Prostate Cancer Prostatic Dis. 1997;1:16-20. (Pubitemid 127537059)
20. Eriksson S, Vehniainen M, Jansen T, et al. Dual-label time-resolved immunofluorometric assay of free and total prostate-specific antigen based on recombinant Fab fragments. Clin Chem. 2000;46:658-666. (Pubitemid 30318421)
21. Rafferty B, Rigsby P, Rose M, et al. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin Chem. 2000;46:1310-1317.
22. Vaisanen V, Eriksson S, Ivaska KK, et al. Development of sensitive immunoassays for free and total human glandular kallikrein 2. Clin Chem. 2004;50:1607-1617. (Pubitemid 39121229)
23. Vaisanen V, Peltola MT, Lilja H, et al. Intact free prostate-specific antigen and free and total human glandular kallikrein. 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab′)2 fragments. Anal Chem. 2006;78:7809-7815.
24. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing V; 2004.
25. Vickers AJ, Wolters T, Savage CJ, et al. Prostate-specific antigen velocity for Early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol. 2009;56:753-760.
26. Stephan C, Kahrs AM, Cammann H, et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate. 2009;69:198-207.
27. Charrier JP, Tournel C, Michel S, et al. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia. Electrophoresis. 1999;20:1075-1081. (Pubitemid 29222470)
28. Steuber T, Nurmikko P, Haese A, et al. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J Urol. 2002;168:1917-1922.
29. Stephan C, Cammann H, Deger S, et al. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network. Urology. 2009;74:873-877.
30. Linton HJ, Marks LS, Millar LS, et al. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem. 2003;49:253-259. (Pubitemid 36143447)